Theranostic NGS Market
Report ID: SQMIG35J2653
Report ID: SQMIG35J2653
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2653 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
154
|Figures:
78
Global Theranostic Ngs Market size was valued at USD 1.87 Billion in 2024 and is poised to grow from USD 1.97 Billion in 2025 to USD 3.01 Billion by 2033, growing at a CAGR of 5.4% during the forecast period (2026-2033).
The global theranostic next‑generation sequencing (NGS) market combines diagnostic genomics with targeted therapy, enabling clinicians to match molecular profiles to precision drugs. Its importance stems from the shift toward personalized medicine, where early detection of actionable mutations reduces treatment delays and improves outcomes. Historically, the market emerged from the convergence of high‑throughput sequencing platforms in the early 2010s and the FDA’s approval of companion diagnostics such as the KRAS test for colorectal cancer. Since then, adoption has accelerated as oncology centers integrate NGS panels into biopsies, exemplified by Memorial Sloan Kettering’s launch of a 500‑gene assay that informs immunotherapy selection.
One key trend driving the global theranostic NGS sector is the expanding reimbursement ecosystem, which transforms technological promise into scalable health‑care solutions. When insurers recognize the cost‑avoidance potential of early‑stage molecular stratification, they finance panel tests, prompting hospitals to invest in automated sequencers and bioinformatics teams. This financial incentive fuels broader clinical trial enrollment, as exemplified by the NCT03772687 study that pairs a 324‑gene NGS assay with a PARP inhibitor, thereby generating real‑world evidence of improved progression‑free survival. Consequently, pharmaceutical firms prioritize companion‑diagnostic co‑development, unlocking new revenue streams and accelerating market penetration across oncology, rare disease, and infectious‑disease segments today.
How is AI Accelerating Personalized Diagnostics in the Theranostic NGS Market?
AI is reshaping personalized diagnostics in the theranostic NGS market by integrating deep learning with genomic sequencing data. Machine‑learning models interpret complex mutation patterns, predict drug response and prioritize biomarkers, enabling clinicians to match patients with targeted therapies faster. Real‑time data pipelines reduce turnaround time and improve accuracy compared with traditional analysis. Cloud‑based platforms allow collaborative interpretation across institutions, expanding access to precision care. As sequencing costs fall, AI‑driven workflows become essential for handling the growing volume of data and for translating molecular insights into actionable treatment plans. These capabilities also support clinical trial enrollment by identifying eligible genomic profiles.
In April 2025, Illumina partnered with Tempus AI to combine AI-driven genomic analytics with next-generation sequencing (NGS) for precision medicine. The collaboration uses multimodal clinical and molecular data to improve biomarker discovery, accelerate companion diagnostic development, and enhance theranostic NGS workflows for personalized treatment selection across multiple disease areas.
Market snapshot - (2026-2033)
Global Market Size
USD 1.87 Billion
Largest Segment
Reagents & Consumables
Fastest Growth
Software & Bioinformatics
Growth Rate
5.4% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global theranostic ngs market is segmented by product type, application, technology, end user, workflow and region. Based on product type, the market is segmented into ngs instruments, reagents & consumables, software & bioinformatics, services and others. Based on application, the market is segmented into oncology, rare disease diagnosis, infectious disease testing, reproductive health and others. Based on technology, the market is segmented into targeted sequencing, whole exome sequencing, whole genome sequencing, RNA sequencing and others. Based on end user, the market is segmented into hospitals, clinical laboratories, research institutes, pharmaceutical & biotechnology companies and others. Based on workflow, the market is segmented into sample preparation, sequencing, data analysis, clinical interpretation and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Based on the global theranostic NGS market growth, reagents & consumables segment dominates because it forms the essential foundation for every NGS workflow, supplying kits, library prep reagents, and sequencing consumables that directly impact assay reliability and turnaround time. Vendors continuously refine chemistry to improve sensitivity and reduce input requirements, meeting the stringent quality standards of clinical laboratories. This persistent demand for high‑performance, cost‑efficient consumables sustains its leadership in the Theranostic NGS Market across global therapeutic pipelines domains.
Meanwhile, software & bioinformatics segment emerges as the fastest growing because artificial intelligence‑driven analysis tools are unlocking deeper clinical insights from complex sequencing data. Integration of cloud‑based pipelines and real‑time interpretation platforms accelerates assay deployment, attracting investment and expanding the market’s capability to deliver personalized therapeutic decisions for clinicians worldwide.
Oncology segment dominates because cancer genomics requires comprehensive, high‑throughput sequencing to guide targeted therapies and monitor disease evolution, creating a constant flow of diagnostic orders. Clinical oncologists rely on NGS to stratify patients, and payors increasingly reimburse panels that demonstrate actionable biomarkers. The deep integration of oncology workflows with hospital informatics reinforces its central role, sustaining robust demand across the Theranostic NGS Market for personalized treatment planning and long‑term survivorship strategies.
On the other hand, rare disease diagnosis segment is witnessing the strongest growth momentum because newborn screening programs and awareness of orphan disorders drive clinicians to adopt NGS for confirmation. Therapeutic approvals for rare conditions amplify testing demand, prompting laboratories to invest in panels that broaden market reach and fuel expansion.
To get detailed segments analysis, Request a Free Sample Report
As per the global theranostic NGS market share, North America leads through a convergence of deep scientific expertise, robust funding mechanisms, and a mature regulatory environment that encourages clinical translation. The region benefits from a dense network of leading academic institutions and biotech innovators that collaborate closely with health‑care providers. Strong venture capital activity fuels rapid development of novel assays and companion diagnostics, while integrated health‑care systems facilitate adoption at scale. A focus on precision medicine initiatives and patient‑centric data ecosystems further consolidates market leadership, creating an environment where new therapeutic insights can be swiftly moved from bench to bedside.
United States Theranostic NGS Market
Theranostic NGS market activity in the United States thrives on an extensive research infrastructure and a highly competitive biotech landscape. Collaboration between academic centers and commercial firms accelerates assay development, while reimbursement pathways support broader clinical implementation. The market is further reinforced by a culture of innovation that attracts top talent and drives continuous refinement of diagnostic algorithms.
Canada Theranostic NGS Market
Theranostic NGS market progress in Canada is propelled by strong government support for health‑care research and a collaborative public‑private framework. Strong ties between national laboratories and local hospitals enable rapid validation of genomic tests, while policy incentives encourage the integration of sequencing technologies into routine care. The emphasis on equitable access ensures that advances reach diverse patient populations across the country.
Based on global theranostic NGS regional forecast, Europe’s expansion is fueled by coordinated policy agendas that prioritize personalized medicine and cross‑border research collaboration. Leading academic hubs and a growing pool of specialized biotech firms create a fertile ground for innovative assay development. Harmonized regulatory standards across the region simplify market entry, while public health initiatives emphasize early detection and targeted therapy, encouraging health‑care systems to adopt genomic solutions. Investment in data sharing platforms and a focus on patient outcomes further accelerates adoption, positioning Europe as a dynamic growth engine for theranostic sequencing.
Germany Theranostic NGS Market
Theranostic NGS market development in Germany is anchored by world‑class research institutions and a strong manufacturing base for diagnostic devices. Close partnerships between universities, hospitals, and industry drive rapid translation of genomic discoveries into clinical practice. Government funding programs reinforce a pipeline of innovative projects, while a well‑established reimbursement framework supports widespread clinical use.
United Kingdom Theranostic NGS Market
Theranostic NGS market expansion in the United Kingdom is propelled by an aggressive focus on genomics within national health strategies. Leading hospitals and research networks collaborate intensively to integrate sequencing into routine oncology pathways. Strong entrepreneurial ecosystems and supportive regulatory guidance foster the emergence of niche diagnostic startups, while public health campaigns raise awareness of precision approaches among clinicians.
France Theranostic NGS Market
Theranostic NGS market activity in France benefits from a strategic emphasis on personalized health care within the national health system. Collaborative research clusters bring together academic scientists and biotech innovators to co‑develop diagnostic assays. Policy incentives encourage clinical trials that incorporate genomic profiling, and efforts to streamline approval processes help bring new tests to patients more efficiently.
As per global theranostic NGS regional outlook, Asia Pacific is advancing its role through a blend of government‑driven innovation agendas, rising investment in biotech, and expanding clinical adoption of genomic technologies. The region’s large, genetically diverse populations provide a rich substrate for research, while evolving regulatory frameworks aim to balance safety with rapid market access. Health‑care systems are increasingly integrating sequencing into standard diagnostic pathways, supported by growing expertise in bioinformatics and data analytics. Collaborative networks linking hospitals, research institutes, and industry accelerate product development, positioning the region as a burgeoning hub for theranostic advancements.
Japan Theranostic NGS Market
Theranostic NGS market growth in Japan is underpinned by a strong tradition of precision medicine research and proactive health‑policy support. Leading universities partner closely with clinical centers to validate genomic tests, while government initiatives promote the incorporation of sequencing into national health guidelines. A focus on technology transfer enhances the commercial readiness of innovative diagnostic platforms.
South Korea Theranostic NGS Market
Theranostic NGS market momentum in South Korea stems from a dynamic biotech sector and forward‑looking health‑care reforms. Close collaboration between academic hospitals and startups accelerates the development of targeted sequencing panels. Policy measures that streamline regulatory review and encourage reimbursement for genomic services help embed theranostic solutions within everyday clinical practice.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Precision Oncology Adoption
Integrated Data Platforms
High Cost of NGS Implementation
Regulatory Uncertainty Across Regions
Request Free Customization of this report to help us to meet your business objectives.
The global theranostic NGS market outlook is highly competitive, led by Illumina Inc., Thermo Fisher Scientific, QIAGEN N.V., Foundation Medicine, Guardant Health, Roche, Agilent Technologies, and BGI Genomics. Competition centers on companion diagnostics, precision oncology, and biomarker discovery. Illumina focuses on pharmaceutical collaborations and comprehensive genomic profiling platforms, while Guardant Health expands liquid biopsy-based companion diagnostics through strategic drug partnerships. Roche and Foundation Medicine strengthen their positions by integrating FDA-approved NGS companion diagnostics with targeted cancer therapies, advancing personalized medicine worldwide.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global theranostic NGS industry is propelled primarily by the rapid adoption of precision oncology, which drives hospitals and labs to integrate comprehensive sequencing panels into treatment pathways, while integrated data platforms that merge bioinformatics, electronic health records and cloud analytics serve as a second catalyst by streamlining variant interpretation and therapeutic matching. The high cost of implementing NGS systems and ongoing reagent expenses remains a key restraint, limiting uptake in cost‑conscious institutions. North America dominates the market thanks to its deep research ecosystem, mature reimbursement models and strong biotech presence, and within the product landscape the reagents and consumables segment retains the largest share because it underpins every sequencing workflow.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 1.87 Billion |
| Market size value in 2033 | USD 3.01 Billion |
| Growth Rate | 5.4% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Theranostic NGS Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Theranostic NGS Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Theranostic NGS Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Theranostic NGS Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Theranostic Ngs Market size was valued at USD 1.87 Billion in 2024 and is poised to grow from USD 1.97 Billion in 2025 to USD 3.01 Billion by 2033, growing at a CAGR of 5.4% during the forecast period (2026-2033).
The theranostic NGS market is shaped by intense rivalry among platform incumbents and fast‑growing biotech firms, with competitive pressure driving frequent M&A activity, strategic partnerships for assay co‑development, and accelerated rollout of AI‑enhanced sequencing pipelines to secure clinical adoption and payer reimbursement. 'Illumina, Inc.', 'Thermo Fisher Scientific Inc.', 'F. Hoffmann-La Roche Ltd.', 'QIAGEN N.V.', 'Agilent Technologies, Inc.', 'Pacific Biosciences of California, Inc.', 'Oxford Nanopore Technologies plc', 'BGI Genomics Co., Ltd.', 'GeneDx Holdings Corp.', 'Personalis, Inc.', 'Foundation Medicine, Inc.', 'Guardant Health, Inc.', 'Natera, Inc.', 'NeoGenomics Laboratories, Inc.', 'Exact Sciences Corporation', 'Tempus AI, Inc.', 'GenomOncology LLC', 'Sophia Genetics SA', '10x Genomics, Inc.', 'Standard BioTools Inc.'
The expanding use of NGS in precision oncology creates a compelling value proposition for clinicians seeking molecularly guided treatment pathways, which in turn motivates healthcare institutions to incorporate theranostic sequencing into routine workflows. This adoption is reinforced by increasing awareness of personalized therapy benefits, fostering collaborative research initiatives and encouraging investment in supportive infrastructure, thereby propelling market momentum without reliance on numerical forecasts. Clinicians also report higher diagnostic confidence, which enhances physician confidence in ordering comprehensive panels and supports reimbursement discussions, further solidifying market expansion.
Precision Oncology Integration: Healthcare providers are embedding NGS‑driven theranostics into standard oncology pathways, enabling clinicians to match targeted therapies with molecular profiles at the point of care. This shift is driven by growing clinical confidence in genomic biomarkers, expanding companion‑diagnostic approvals, and the desire to improve patient outcomes while reducing trial‑and‑error prescribing. As multidisciplinary tumor boards adopt genomic data as a core decision tool, the market experiences heightened demand for integrated platforms that deliver faster, more accurate, and actionable insights across cancer types.
Why does North America Dominate the Global Theranostic NGS Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
